Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients

AIDS

Volumn 21, Issue 2, 2007, Pages 169-178

  Ruiz, Lidia ^a,b   Paredes, Roger ^a,b   Gómez, Guadalupe ^c   Romeu, Joan ^a,b   Domingo, Pere ^d   Pérez Alvarez, Nuria ^a,b,c   Tambussi, Giuseppe ^e   Llibre, Josep Maria ^f   Martínez Picado, Javier ^a,b   Vidal, Francesc ^g   Fumaz, Carmina R ^a,b   Clotet, Bonaventura ^a,b   Sirera, G ^a   Miranda, C ^a   Negredo, E ^a   Jou, A ^a   Tural, C ^a   Miranda, J ^a   Martinez J C ^a   Fuster, M ^d   Veloso, S ^g   Peraire, J ^g   Vilades, C ^g   Valero, S ^f   Nozza, S ^e   Bofill, Margarita ^a   Bellido, Rocío ^a   Grau, Eulàlia ^a   Ayen, Rafaela ^a   Calle, M L ^h   Espinal, A ^d   Serrat, Carles ^c   Huertas, J ^c   more..

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^c UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f Hospital de Calella   (Spain)

^g HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^h UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

Author keywords

CD4 cell count; Chronic HIV infection; Guided treatment interruption; HIV 1 RNA level

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACUTE ANTIRETROVIRAL SYNDROME; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ERUPTION; DRUG EXPOSURE; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; KIDNEY COLIC; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MONONUCLEOSIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATION; MUTATIONAL ANALYSIS; MYALGIA; PANCREATITIS; PARESTHESIA; PHARYNGITIS; POLYNEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; RNA ANALYSIS; SIDE EFFECT; SOCIAL PSYCHOLOGY; STANDARD; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY OF LIFE; RNA, VIRAL; VIRAL LOAD;

EID: 33845921356     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328011033a     Document Type: Article

References (29)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1998; 338:853-860.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
3. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. New Engl J Med 1999; 340:1605-1613.
4. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+s. Nat Med 2003; 9:727-728.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
7. Harrington M, Carpenter C. Hit HIV-1 hard, but only when necessary. Lancet 2000; 355:2147-2152.
8. Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 2000; 132:306-311.
9. Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Update of the drug resistance mutations in HIV-1: 2004. Topics HIV Med 2004; 12:119-124.
10. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, October 6, 2005. Available at: http://aidsinfo.nih.gov.
11. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
12. Tarwater P, Parish M, Gallant J. Prolonged treatment interruption after immunologic response to highly active therapy. Clin Infect Dis 2003; 37:1541-1548.
13. 6 cells/l. AIDS 2005; 19:287-294.
14. Nuasch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, et al. Development of HIV with drug resistance after CD4 cell-count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 2005; 40:728-734.
15. Skiest DJ, Morrow P, Allen B, McKinsey J, Crosby C, Foster B, et al. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/μL. J Acquir Immune Defic Syndr 2004; 37:1351-1357.
16. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40:594-600.
17. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4s: a controlled, prospective trial. AIDS 2004; 18:439-446.
18. 3. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 101].
19. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, et al. CD4 guided scheduled treatment interruption compared to continuous therapy: Results of the Staccato Trial. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 102].
20. 6 cells/l. AIDS 2005; 19:53-61.
21. El-Sadr W, Neaton J, for the SMART Study Investigators. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART Study. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 106LB].
22. Danel C, Moh R, Sorho S, Minga A, Anzian A, Ba-Gomis O, et al. The CD4-guided strategy arm stopped in a randomized structured treatment interruption trial in West-African adults: ANRS 1269 Trivacan Trial. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 105LB].
23. Tuldrà A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 15 (31 Suppl 3):S154-S157.
24. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
25. Wu Aw, Rubin HR, Mathews WC, Ware JE Jr, Brysk LT, Hardy WD, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care 1991; 29:786-798.
26. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
27. Schacker T, Collier AC, Hugues J, Shea T, Corey L. Clinical and epidemiological features of primary HIV infection. Ann Intern Med 1996; 125:257-264.
28. Ribaudo H, Clifford D, Gulick R, Shikuma C, Klingman K, Snyder S, et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTG A5095/A5097s. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 132].
29. Taylor S, Allen S, Fidler S, White D, Gibbons S, Fox J, et al. Stop study: after discontinuation of efavirenz, plasma concentrations may persist for two weeks or longer. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 131].